Vancocin Generic In Vivo Testing Waiver Is Not Scientifically Sound, ViroPharma Says
This article was originally published in The Pink Sheet Daily
More stringent testing is needed because the product treats two potentially life-threatening diseases, the firm argues in a supplement to its Petition for Stay of Action.
You may also be interested in...
The firm, which markets vancomycin hydrochloride, says FDA decision on bioequivalence testing violates FOIA and other statutes.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.